Affiliation:
1. Tommy's Centre for Maternal and Fetal Health at the MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, United Kingdom
2. Tohoku University Hospital, Sendai, Miyagi, Japan
Abstract
Background:
Between 5-15% of babies are born prematurely worldwide, with preterm birth defined as
delivery before 37 completed weeks of pregnancy (term is at 40 weeks of gestation). Women at risk of preterm
birth receive antenatal corticosteroids as part of standard care to accelerate fetal lung maturation and thus improve
neonatal outcomes in the event of delivery. As a consequence of this treatment, the entire fetal organ system is
exposed to the administered corticosteroids. The implications of this exposure, particularly the long-term impacts
on offspring health, are poorly understood.
Aims:
This review will consider the origins of antenatal corticosteroid treatment and variations in current clinical
practices surrounding the treatment. The limitations in the evidence base supporting the use of antenatal corticosteroids
and the evidence of potential harm to offspring are also summarised.
Results:
Little has been done to optimise the dose and formulation of antenatal corticosteroid treatment since the
first clinical trial in 1972. International guidelines for the use of the treatment lack clarity regarding the recommended
type of corticosteroid and the gestational window of treatment administration. Furthermore, clinical trials
cited in the most recent Cochrane Review have limitations which should be taken into account when considering
the use of antenatal corticosteroids in clinical practice. Lastly, there is limited evidence regarding the long-term
effects on the different fetal organ systems exposed in utero, particularly when the timing of corticosteroid administration
is sub-optimal.
Conclusion:
Further investigations are urgently needed to determine the most safe and effective treatment regimen
for antenatal corticosteroids, particularly regarding the type of corticosteroid and optimal gestational window
of administration. A clear consensus on the use of this common treatment could maximise the benefits and minimise
potential harms to offspring.
Funder
Wellcome Trust Clinical Research Career Development Fellowship
MRC Centre for Reproductive Health
Tommy’s charity
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献